Gould F Kate, Brindle Richard, Chadwick Paul R, Fraise Adam P, Hill Simon, Nathwani Dilip, Ridgway Geoff L, Spry Michael J, Warren Rod E
Department of Microbiology, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK.
J Antimicrob Chemother. 2009 May;63(5):849-61. doi: 10.1093/jac/dkp065. Epub 2009 Mar 12.
These evidence-based guidelines are an updated version of those published in 2006. They have been produced after a literature review of the treatment and prophylaxis of methicillin-resistant Staphylococcus aureus (MRSA). The guidelines aim to complement those recently published for the antibiotic treatment of common and emerging community-onset MRSA infections in the UK. The guidelines have reviewed and updated, where appropriate, previous recommendations, taking into account any changes in the UK epidemiology of MRSA, ongoing national surveillance data and the value of new antistaphylococcal agents licensed for use in UK practice. Emerging therapies that have not been licensed for UK use are not reviewed, but their future potential role has been mentioned where deemed appropriate. Recommendations are given for the treatment of common infections caused by MRSA, elimination of MRSA from carriage sites and prophylaxis of surgical site infection.
这些循证指南是2006年发布版本的更新版。它们是在对耐甲氧西林金黄色葡萄球菌(MRSA)的治疗和预防进行文献综述后制定的。这些指南旨在补充英国最近发布的关于常见和新出现的社区获得性MRSA感染抗生素治疗的指南。指南在适当的地方对以前的建议进行了审查和更新,同时考虑到英国MRSA流行病学的任何变化、持续的国家监测数据以及在英国实践中获得许可使用的新型抗葡萄球菌药物的价值。未在英国获得许可使用的新兴疗法未作审查,但在认为适当时提及了它们未来可能发挥的作用。给出了关于MRSA引起的常见感染的治疗、从携带部位清除MRSA以及手术部位感染预防的建议。